Medical Oncology 2015 February [Link] de Lima VA, Sorensen JB. Abstract There is no well-defined standard third-line chemotherapy for advanced malignant pleural mesothelioma (MPM). However, combination of carboplatin, liposomised doxorubicin (Caelyx) and gemcitabine (CCG regimen) has revealed noteworthy activity when used as first-line treatment. The aim of this study is to assess efficacy and toxicity…

Read More

Journal of Thoracic Oncology. 2008 Nov;3(11):1325-31. [Link] Hillerdal G, Sorensen JB, Sundström S, Riska H, Vikström A, Hjerpe A. Department of Lung Medicine and Allergology, Karolinska University Hospital, Solna, Stockholm, Sweden. gunnar.hillerdal@karolinska.se Abstract Background: Malignant pleural mesothelioma has a poor prognosis and there is limited effect of treatment. The Nordic Mesothelioma groups decided in the…

Read More

Current Treatment Options in Oncology. 2008 Jun;9(2-3):180-90. Epub 2008 Oct 8. [Link] Hesdorffer ME, Chabot J, DeRosa C, Taub R. Mesothelioma Applied Research Foundation, Santa Barbara, CA, USA. mhesdorer@curemeso.org Abstract Opinion statement: Malignant peritoneal mesothelioma (MPM) is an aggressive neoplasm that rapidly spreads within the confines of the abdominal cavity to involve most accessible peritoneal…

Read More

Surgical Laparoscopy, Endoscopy & Percutaneous Techniques. 2008 Aug;18(4):426-8. [Link] Patriti A, Cavazzoni E, Graziosi L, Pisciaroli A, Luzi D, Gullà N, Donini A. Section of General and Emergency Surgery, Department of Surgery, University of Perugia, Perugia, Italy. albertopatriti@gmail.com Abstract A variety of options have been proposed to treat malignant ascites but most of them have…

Read More

Cancer Chemotherapy and Pharmacology. 2008 Jul 25. [Epub ahead of print] [Link] Van der Speeten K, Stuart OA, Mahteme H, Sugarbaker PH. Department of Surgical Oncology, Ziekenhuis Oost-Limburg, Schiepse Bos 6, 3600, Genk, Belgium, kurt.vanderspeeten@zol.be. Abstract Purpose: A pharmacologic analysis of intracavitary doxorubicin in the treatment of patients with intracavitary cancer dissemination was performed to…

Read More

Annals of Surgical Oncology. 2008 May;15(5):1407-13. Epub 2007 Dec 22. [Link] Harrison LE, Bryan M, Pliner L, Saunders T. Division of Surgical Oncology, UMDNJ-New Jersey Medical School, 185 South Orange Ave, Newark, NJ 07103, USA. L.Harrison@umdnj.edu Abstract Background: Cytoreduction coupled with hyperthermic intraperitoneal chemotherapy (HIPEC) is an attractive treatment option for a select group of…

Read More

In Vivo. 2008 Jan-Feb;22(1):153-7. [Link] Baratti D, Kusamura S, Sironi A, Cabras A, Fumagalli L, Laterza B, Deraco M. Department of Surgery, National Cancer Institute, Milan, Italy. Abstract Background: Multicystic peritoneal mesothelioma (MPM) is an extremely uncommon lesion with uncertain malignant potential. Multiple recurrences after surgical interventions and transition to aggressive malignancies have been reported.…

Read More

European Respiratory Journal. 2008 Apr 2 [Epub ahead of print] [Link] Riganti C, Doublier S, Aldieri E, Orecchia S, Betta PG, Gazzano E, Ghigo D, Bosia A. Biology and Biochemistry, University of Torino; and Research Center on Experimental Medicine (CeRMS), Via Santena 5/bis, 10126 Torino, Italy. Abstract Human malignant mesothelioma (HMM), which is strongly related…

Read More

American Journal of Clinical Oncology. 2008 Feb;31(1):49-54 [Link] Hesdorffer ME, Chabot JA, Keohan ML, Fountain K, Talbot S, Gabay M, Valentin C, Lee SM, Taub RN. Division of Oncology, Columbia University New York, New York, USA. mhesdorffer@curemeso.org Abstract Objective: We report a single-institution Phase I or II trial of surgical debulking, intraperitoneal chemotherapy, and immunotherapy…

Read More